EcoDrugPlus

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSLCAG00010009555
Gene Symbol: NAMPT
4 Cross references
225 Possible Orthologues:

Nischarin

Ensembl ID : ENSLCAG00010004178
Gene Symbol: LOC108889790
3 Cross references
208 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSLCAG00010025861
Gene Symbol: NOTCH3
1 Cross references
172 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSLCAG00010006790
Gene Symbol: NFKB1
1 Cross references
199 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 3

Ensembl ID : ENSLCAG00010018835
Gene Symbol: LOC108887816
4 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 4

Ensembl ID : ENSLCAG00010016228
Gene Symbol: LOC108875375
4 Cross references
385 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSLCAG00010019875
Gene Symbol: NR3C1
4 Cross references
205 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSLCAG00010015384
Gene Symbol: NR3C1
4 Cross references
205 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 2

Ensembl ID : ENSLCAG00010019366
Gene Symbol: LOC108893065
4 Cross references
204 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSLCAG00010016222
Gene Symbol: LOC108876863
4 Cross references
166 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSLCAG00010005048
Gene Symbol: OPRD1
4 Cross references
191 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSLCAG00010006238
Gene Symbol: OPRK1
4 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).